https://www.selleckchem.com/PARP.html
To review the efficacy, safety, and available literature regarding the novel combination bioidentical product Bijuva, or 17β-estradiol/progesterone (17β-E/P), for the treatment of moderate to severe menopausal symptoms in cisgender females with an intact uterus. Literature searches of both PubMed (1966 to October 202 and Google Scholar were conducted using search terms including , and . All articles with studies conducted in cisgender human females and in the English language were considered for review; 18 publications were included. In 1 phase 3
Like
Comment
Share
